# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT S94a21e28a4
CUTOFF DATE (today): 2020-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Saa91e0e4a6
CUTOFF DATE (today): 2020-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Drug Products Labeled as Homeopathic
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sa74d2c9e9b
CUTOFF DATE (today): 2024-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-11-01 | official-forward (B) | draft_guidance_availability_notice | "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials." The purpose of this draft guidance is to outline the most appropriate methods for measuring a
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials." The purpose of this draft guidance is to outline the most appropriate methods for measuring and recording growth and evaluating pubertal development for drugs or biological products in development for pediatric use when such an assessment is necessary to support safety. This draft guidance is intended to encourage a consistent approach to collecting interpretable and accurate growth and pubertal development data. This draft guidance does not address use of growth or pubertal development data to support primary evidence of efficacy in growth disorders and does not address evaluation of nutritional status.
---
## SNAPSHOT Sa2f95e0198
CUTOFF DATE (today): 2026-01-01
Regulator: SEBI (IN)
Matter: SEBI consultation: proposed amendments to the certification regime for associated persons in the securities markets
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-11-06 | official-forward (B) | consultation_paper | "Consultation paper on Amendments to SEBI (Certification of Associated Persons in the Securities Markets) Regulations, 2007" | www.sebi.gov.in
   Claims: Proposes reviewing/expanding the definition of 'Associated Persons' under CAPSM Regulations, 2007. / Proposes changes to the manner of obtaining the NISM certificate required under the regulations. / Proposes allowing an electronic mode of participation for Continuing Professional Education (CPE) programs. / Proposes reviewing the exception criteria governing the manner of obtaining the certificate (e.g. age/experience-based exemptions).
   Excerpt: To solicit comments / views / suggestions from the public and other stakeholders on the proposed amendments to 'SEBI (Certification of Associated Persons in the Securities Markets) Regulations, 2007 ("CAPSM Regulations")'. The following proposals are being made: 1.1.1 Review / Expansion of the definition of 'Associated Persons' 1.1.2 Manner of obtaining certificate 1.1.3 Inclusion of electronic mode of participation for Continuing Professional Education (CPE) programs 1.1.4 Reviewing the exception criteria for manner of obtaining certificate.
---
## SNAPSHOT S43bbd372ed
CUTOFF DATE (today): 2023-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S39334702c8
CUTOFF DATE (today): 2026-07-26
Regulator: SEBI (IN)
Matter: SEBI consultation: aligning Trading Member position limits in the Equity Derivatives Segment with the client-level Futures-Equivalent metric
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-12-04 | official-forward (B) | consultation_paper | "Consultation Paper: Review of existing position limits for Trading Members in Equity Derivatives Segment" | www.sebi.gov.in
   Claims: Seeks feedback on calculating and aligning Trading Member (TM) index-derivatives position limits using the Futures-Equivalent (FutEq) metric. / Notes client-level index-options position limits already moved to FutEq value via a May 29, 2025 circular (INR 1,500 Cr net FutEq, or INR 10,000 Cr gross long/short FutEq per index). / Notes TM-level limits, last stipulated by an October 15, 2024 circular, remain based on notional contract value, creating a metric mismatch when SEBI aggregates client positions to the TM level.
   Excerpt: SEBI, vide circular dated May 29, 2025, stipulated the client / entity level position limits for index options in terms of Futures Equivalent (FutEq) value of options contracts. The Trading Members (TMs) limits for index options, last stipulated vide circular dated October 15, 2024, are based on the notional value of the options contracts. As monitoring of position limits of TMs require aggregating the positions of clients of TMs, there is at present non-alignment in metric of positions measurement at client level and that at TM level. This consultation paper seeks feedback with regard to calculation and alignment of the existing TM position limits in terms of FutEq metric.
---
## SNAPSHOT S460776ba14
CUTOFF DATE (today): 2023-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sed18ef8413
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: phased introduction of physical settlement in select agricultural commodity derivatives contracts
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sb0eb53095e
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S85a88f2f9d
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: draft circular on trading software/technology at stock exchanges and common IT provisions for market infrastructure institutions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sd9917ab49d
CUTOFF DATE (today): 2020-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S4258272c1b
CUTOFF DATE (today): 2020-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products-Content and Format
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2019-07-01 | official-forward (B) | draft_guidance_availability_notice | "Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products-Content and Format; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Instructions for Use--Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products--Content and Format." This dr
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Instructions for Use--Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products--Content and Format." This draft guidance provides recommendations for developing the content and format of an Instructions for Use (IFU) document for human prescription drugs and biological products and drug-device or biologic-device combination products submitted under a new drug application (NDA) or a biologics license application (BLA). The IFU is developed by applicants for patients who use drug products that have complicated or detailed patient-use instructions. The recommendations in this draft guidance are intended to help develop consistent content and format across IFUs and to help ensure that patients receive clear, concise information that is easily understood for the safe and effective use of prescription drug products.
---
## SNAPSHOT S5421516797
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: harmonizing base price for pre-open call auction and price bands for stocks listed on multiple exchanges
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-06-11 | official-forward (B) | consultation_paper | "Consultation Paper on Harmonization of Base price for Call Auction in Pre-open Session and for Price Band - For scrips listed on multiple stock exchanges" | www.sebi.gov.in
   Claims: Seeks public comments on proposals to harmonize the base price for the pre-open call-auction session, and price bands, for scrips listed on more than one recognized stock exchange. / Notes existing rule (Master Circular Para 2.3) prescribing individual scrip-wise price bands of up to 20% either way for scrips without derivatives products. / Notes existing rule (Master Circular Para 17.1.6) that price bands in the pre-open session equal those applicable in the normal market. / Frames the issue as inconsistency that can arise when a scrip is listed on multiple exchanges, each of which may independently apply these base-price/price-band rules.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals to harmonize the base price for call auction in pre-open session and for setting up price bands for scrips listed on multiple stock exchanges. Background: As a measure against excessive price movements, SEBI vide circular No. SMDRPD/Policy/Cir-37/2001 dated June 28, 2001 has advised stock exchanges to implement individual scrip wise price bands of 20% either way, for all scrips in compulsory rolling settlement except for the scrips on which derivatives products are available or scrips included in indices on which derivatives products are available.
---
## SNAPSHOT Sfa4967c922
CUTOFF DATE (today): 2022-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: The Use of Published Literature in Support of New Animal Drug Applications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S8fb2fb3798
CUTOFF DATE (today): 2026-07-26
Regulator: SEBI (IN)
Matter: SEBI consultation: treatment of debt-funded major maintenance expenses in Net Distributable Cash Flow calculation for Infrastructure Investment Trusts
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S321a6d3bac
CUTOFF DATE (today): 2024-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Mpox: Development of Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-01-20 | official-forward (B) | draft_guidance_availability_notice | "Mpox: Development of Drugs and Biological Products; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Mpox: Development of Drugs and Biological Products." FDA is issuing this guidance to support sponsors in their development of drugs and biological products for mpox.
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Mpox: Development of Drugs and Biological Products." FDA is issuing this guidance to support sponsors in their development of drugs and biological products for mpox.
---
## SNAPSHOT S0c6eca3dfd
CUTOFF DATE (today): 2026-01-01
Regulator: SEBI (IN)
Matter: SEBI consultation: ease-of-doing-business modifications to master circular provisions on administration of stock exchanges
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-10-08 | official-forward (B) | consultation_paper | "Consultation Paper on Measures for ease of doing business on Administration of Exchanges" | www.sebi.gov.in
   Claims: First in a series of ease-of-doing-business consultation papers reviewing SEBI's exchange-related master circulars, implementing a FY2023-24 budget announcement on consultative compliance simplification. / Proposes modifications to Chapter 6 (Administration of Stock Exchanges) of the Master Circular for Stock Exchanges and Clearing Corporations, and related chapters of the Master Circular for Commodity Derivatives Segment. / Covers administration of stock exchanges including commodity derivatives exchanges.
   Excerpt: CONSULTATION PAPER ON ADMINISTRATION OF STOCK EXCHANGES- FOR PUBLIC COMMENTS. Measures for ease of doing business for MIIs- " Modifications to Master Circular for Stock Exchanges and Clearing Corporations, Master Circular for Commodity Derivatives Segment on Administration of Stock Exchanges (including Commodity Derivatives Exchanges)". The Hon'ble Finance Minister in the budget announcements for FY 2023-24, inter-alia, made an announcement to simplify, ease and reduce cost of compliance for participants in the financial sector through a consultative process.
---
## SNAPSHOT S4c37a5dac1
CUTOFF DATE (today): 2024-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S6e84d5a1d1
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: framework for an IT Resilience Index for market infrastructure institutions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-03-25 | official-forward (B) | consultation_paper | "Consultation Paper on Framework of IT Resilience Index for Market Infrastructure Institutions (MIIs)" | www.sebi.gov.in
   Claims: Proposes creation of an 'IT Resilience Index' (ITRI) for market infrastructure institutions, computed periodically on a pre-decided set of parameters. / States the objective is to let MIIs compare the health/efficacy of their IT systems over time and to create a uniform set of metrics and weights to compare ITRI across MIIs. / Notes MIIs had already built a working model of the index, discussed in meetings of SEBI's Technical Advisory Committee (TAC).
   Excerpt: The objective of the consultation paper is to seek views on creation of IT Resilience Index (ITRI) for MIIs that would be computed periodically on a pre-decided set of parameters and which would provide insights to the MII on health of its IT systems across various dimensions. Based on the discussions with MIIs, an initial framework of ITRI for MIIs was formulated. The MIIs have implemented a working model of such index and the results were subsequently discussed in various meetings of SEBI's Technical Advisory Committee (TAC).
---
## SNAPSHOT S1128beafbf
CUTOFF DATE (today): 2022-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-06-28 | official-forward (B) | draft_guidance_availability_notice | "Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Sponsor Responsibilities--Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/ Bioequivalence Studies." The draft gu
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Sponsor Responsibilities--Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/ Bioequivalence Studies." The draft guidance provides recommendations for sponsors and sponsor-investigators to comply with the requirements of investigational new drug application (IND) safety reporting and safety reporting for bioavailability (BA) and bioequivalence (BE) studies. In doing so, the guidance provides recommendations related to the two IND safety reporting provisions that require assessment of aggregate data to facilitate appropriate IND safety reporting practices. An earlier draft guidance for industry entitled "Safety Assessment for IND Safety Reporting" (December 2015) (the 2015 draft guidance) has been incorporated into this draft guidance. However, this content was revised to address feedback from stakeholders and comments received on the 2015 draft guidance. Concurrent with the publication of this draft guidance, we are withdrawing the 2015 draft guidance. Additionally, this draft guidance incorporates c